青少年2型糖尿病随机分组时及治疗反应中的胰岛素清除率:TODAY随机临床试验的二次分析
本文为TODAY随机临床试验的二次分析,纳入640例10-18岁2型糖尿病青少年,纵向随访5年。研究发现基线空腹胰岛素清除率在女性低于男性,非西班牙裔黑人低于西班牙裔及非西班牙裔白人;较低胰岛素清除率与体重增加及其他肥胖和胰岛素敏感性指标相关,而与β细胞功能无关。与单用二甲双胍相比,二甲双胍联合罗格列酮时胰岛素清除率更高,但校正脂联素后差异无统计学意义。
要点
- 女性青少年2型糖尿病患者基线空腹胰岛素清除率显著低于男性。
- 非西班牙裔黑人青少年胰岛素清除率显著低于西班牙裔和非西班牙裔白人。
- 胰岛素清除率随体重增加而降低,但与β细胞功能无关。
核心结论
- 在青少年2型糖尿病中,低胰岛素清除率与女性、非西班牙裔黑人种族和族裔以及肥胖和胰岛素抵抗标志物相关,但与β细胞功能无关。
- 与胰岛素敏感性和脂联素一样,胰岛素清除率在罗格列酮治疗反应中升高。
- 这些发现提示,在青少年起病2型糖尿病中,低胰岛素清除率是对胰岛素敏感性和/或脂联素浓度变化的代偿性反应,而非β细胞功能的中介因素。
研究设计与样本
- TODAY随机临床试验的二次分析,共纳入640例10-18岁2型糖尿病青少年,纵向随访5年。
- 受试者接受空腹血液检查、人体测量、双能X线吸收法估计皮下脂肪组织和内脏脂肪组织质量,以及口服葡萄糖耐量试验。
- 胰岛素清除率通过空腹C肽与胰岛素比值(空腹胰岛素清除率)和2小时口服葡萄糖耐量试验C肽增量曲线下面积与胰岛素增量曲线下面积比值(2小时胰岛素清除率)计算。
- 采用线性混合模型评估协变量对重复时间点胰岛素清除率均值的影响。
主要发现
- 基线空腹胰岛素清除率(×10⁻² nmol/pmol)女性低于男性(中位数[四分位距] 0.72 [0.57-0.93] vs 0.79 [0.63-1.00],p=0.04)。
- 基线空腹胰岛素清除率非西班牙裔黑人低于西班牙裔和非西班牙裔白人(中位数[四分位距] 0.64 [0.51-0.81] vs 0.78 [0.64-1.00] vs 0.84 [0.68-1.01],p<0.0001);2小时胰岛素清除率结果类似。
- 体重每增加5 kg,空腹胰岛素清除率变化百分比为-1.52 [95% CI -2.05, -0.99],2小时胰岛素清除率为-3.46 [95% CI -4.05, -2.86]。
- 较低的胰岛素清除率还与较高的BMI、皮下脂肪组织质量、腰高比、内脏脂肪组织质量、内脏脂肪与皮下脂肪质量比、甘油三酯浓度、甘油三酯与HDL-胆固醇比值、天冬氨酸氨基转移酶和丙氨酸氨基转移酶浓度、收缩压和舒张压,以及较低的HDL-胆固醇和总脂联素及高分子量脂联素浓度相关。
- 与单用二甲双胍相比,二甲双胍联合罗格列酮时胰岛素清除率更高(空腹胰岛素清除率p=0.03;2小时胰岛素清除率p=0.02);与二甲双胍联合生活方式干预相比,2小时胰岛素清除率更高(p=0.005);但校正脂联素后所有比较p值均不显著。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Insulin resistance and compensatory hyperinsulinaemia are core features leading to beta cell failure in youth-onset type 2 diabetes. Insulin clearance (IC) is also a key regulator of insulin concentrations, but few data exist on IC in youth-onset type 2 diabetes. In a secondary analysis of our Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) randomised clinical trial, we investigated potential sex-, race-, ethnicity- and treatment-related differences in IC in youth-onset type 2 diabetes and aimed to identify metabolic phenotypes associated with IC at baseline and in response to metformin, metformin plus a lifestyle intervention, and metformin plus rosiglitazone. METHODS: A total of 640 youth aged 10-18 years with type 2 diabetes underwent fasting blood tests, anthropometric measurements, dual-energy x-ray absorptiometry to estimate subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) mass, and OGTTs longitudinally over 5 years. IC was calculated from the fasting C-peptide:insulin ratio (fasting IC) and 2 h OGTT C-peptide incremental AUC (iAUC):insulin iAUC ratio (2 h IC). Linear mixed models were used to assess covariate effects on the mean of IC over repeated time points. RESULTS: Baseline fasting IC (×10-2 nmol/pmol) was significantly lower in female participants than male participants (median [IQR] 0.72 [0.57-0.93] vs 0.79 [0.63-1.00], respectively; p=0.04) and in non-Hispanic Black participants than Hispanic and non-Hispanic White participants (median [IQR] 0.64 [0.51-0.81] vs 0.78 [0.64-1.00] vs 0.84 [0.68-1.01], respectively; p<0.0001). Similar results were observed for 2 h IC. Lower IC most strongly correlated with higher weight over time (% change [95% CI] in IC per 5 kg increase: fasting IC -1.52 [-2.05, -0.99]; 2 h IC -3.46 [-4.05, -2.86]). Lower IC also correlated with other markers of adiposity (higher BMI and SAT mass), and markers of insulin sensitivity (higher waist:height ratio, VAT mass, VAT:SAT mass ratio, triacylglycerol concentrations, triacylglycerol:HDL-cholesterol ratio, aspartate aminotransferase [AST] and alanine aminotransferase [ALT] concentrations, and systolic and diastolic BP, and lower HDL-cholesterol and total and high molecular weight adiponectin concentrations) over time. Beta cell function as determined from OGTTs, not insulin sensitivity or IC, was predictive of persistently elevated blood glucose levels. IC was higher with metformin+rosiglitazone than metformin alone (p=0.03 for fasting IC; p=0.02 for 2 h IC) and metformin+lifestyle (2 h IC, p=0.005), but not after adjusting for adiponectin (p value not significant for all). CONCLUSIONS/INTERPRETATION: In youth with type 2 diabetes, low IC is correlated with female sex, non-Hispanic Black race and ethnicity, and markers of adiposity and insulin resistance, but not with beta cell function. Along with insulin sensitivity and adiponectin, IC increased in response to rosiglitazone treatment. These findings suggest that, in youth-onset type 2 diabetes, low IC is a compensatory response to changes in insulin sensitivity and/or adiponectin concentrations and is not a mediator of beta cell function. TRIAL REGISTRATION: ClinicalTrials.gov NCT00081328 DATA AVAILABILITY: Data from the TODAY study (V4; https://doi.org/10.58020/2w6w-pv88 ) reported here are available on request from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository (NIDDK-CR) Resources for Research ( https://repository.niddk.nih.gov/ ).
引用
- Nadeau KJ, Arslanian SA, Bacha F, et al. Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial. Diabetologia. 2024. PMID: 39706874. doi:10.1007/s00125-024-06327-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。